# reload+after+2024-01-20 01:43:18.951682
address1§323 Allerton Avenue
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 466 7125
website§https://www.alxoncology.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
fullTimeEmployees§71
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Corey S. Goodman Ph.D.', 'age': 72, 'title': 'Executive Chairman', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 84000, 'exercisedValue': 0, 'unexercisedValue': 27609}, {'maxAge': 1, 'name': 'Mr. Jason W. Lettmann', 'age': 46, 'title': 'CEO & Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 60500, 'exercisedValue': 0, 'unexercisedValue': 27609}, {'maxAge': 1, 'name': 'Dr. Jaume  Pons Ph.D.', 'age': 57, 'title': 'Founder, President, Director & Chief Scientific Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 856286, 'exercisedValue': 0, 'unexercisedValue': 7912571}, {'maxAge': 1, 'name': 'Mr. Peter S. Garcia M.B.A.', 'age': 61, 'title': 'Chief Financial Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 631114, 'exercisedValue': 0, 'unexercisedValue': 1146455}, {'maxAge': 1, 'name': 'Dr. Sophia  Randolph M.D., Ph.D.', 'age': 55, 'title': 'Chief Medical Officer & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 637238, 'exercisedValue': 0, 'unexercisedValue': 771820}, {'maxAge': 1, 'name': 'Dr. Michael  Chang Ph.D.', 'title': 'Vice President of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Shelly  Pinto', 'age': 47, 'title': 'Senior VP of Finance & Chief Accounting Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 508263, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher  Byrd J.D., Ph.D.', 'title': 'General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Athanasios  Tsiatis M.D.', 'title': 'Senior Vice President of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lin  Yeong-Liang M.D., M.S.', 'title': 'Senior Vice President of Drug Safety & Pharmacovigilance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§5
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.658
currency§USD
dateShortInterest§1702598400
forwardEps§-3.41
exchange§NMS
quoteType§EQUITY
shortName§ALX Oncology Holdings Inc.
longName§ALX Oncology Holdings Inc.
firstTradeDateEpochUtc§1594992600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§52e646b9-c1df-34ee-b25a-cfac131940e6
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§10.0
targetMeanPrice§16.92
targetMedianPrice§17.75
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§5.424
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
